VioOne HIV Profile Supplemental Assay
Primary Purpose
HIV Infections
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
VioOne HIV Profile Supplemental Assay
Sponsored by
About this trial
This is an interventional screening trial for HIV Infections
Eligibility Criteria
Inclusion Criteria:
- Specificity = 280 Serum Samples and 300 Plasma Samples
- An additional 20 Serum pediatric samples
- From low risk population (e.g. blood donors)
Sensitivity = 757 Total Samples
- 400 HIV positive,
- 200 HIV-2 positive
- 50 AIDS positive
- 40 Pediatric
- 15 HIV-O positive
- 10 HIV-1/HIV-2 co-infected positive
- 27 samples from pregnant females with HIV
Sites / Locations
- Avioq Inc
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
VioOne HIV Profile
Arm Description
HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2. It is intended as an additional, more specific test to confirm the presence of antibodies to HIV-1 and HIV-2 for specimens repeatedly reactive in diagnosis or screening procedures, including pediatric patients (ages 2-20).
Outcomes
Primary Outcome Measures
Clinical specificity and sensitivity of HIV Infection
Clinical Specificity and 95% CI of the Profile Assay Clinical Sensitivity and 95% CI of the Profile Assay
Secondary Outcome Measures
Full Information
NCT ID
NCT03727932
First Posted
October 25, 2018
Last Updated
November 1, 2018
Sponsor
Avioq, Inc.
Collaborators
Clinical Reference Laboratory, Duke Clinical Research Institute, University of North Carolina
1. Study Identification
Unique Protocol Identification Number
NCT03727932
Brief Title
VioOne HIV Profile Supplemental Assay
Official Title
VioOne™ HIV Profile™ Supplemental Assay
Study Type
Interventional
2. Study Status
Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
January 3, 2018 (Actual)
Primary Completion Date
April 11, 2018 (Actual)
Study Completion Date
April 11, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Avioq, Inc.
Collaborators
Clinical Reference Laboratory, Duke Clinical Research Institute, University of North Carolina
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Assessment of the sensitivity, specificity and reproducibility of the VioOne HIV Profile Supplemental Assay
Detailed Description
Specificity A total of 280 serum samples and 300 plasma samples from a low-risk population (e.g. blood donors) will be collected at Houston Gulf Coast Regional Blood Center (Houston, TX). All serum and plasma specimens will be previously screened and found non-reactive with FDA licensed or approved HIV-1/2 assays (a population of samples that would not normally be tested with the Avioq VioOne™ HIV Profile™ Supplemental Assay). The number of serum samples will be supplemented up to 300 with the inclusion of 20 pediatric samples; 10 from children aged 2 - 11 and 10 from children aged 12-18 for a total of 600 samples for specificity testing. Samples will be tested with one of three validation kit lots of the Avioq VioOne TM HIV Profile™ Supplemental Assay manufactured at Avioq.
The samples will be tested at 3 external sites in proportions based on the manufacturing size of the individual validation lots. At Site 1 the samples will be further divided approximately 70% I 30% between Validation lots 1 & 2. At Site 2 the samples will be divided approximately 70% / 30%, between Validation lots 2 and 3. At site 3 the samples will be tested entirely with Validation lot 3. The study design calls for the use of at least one lot in common at all 3 clinical sites based on a request from the FDA.
For the Specificity Study, any indeterminate or reactive samples will be tested with either the FDA approved Bio-Rad Geenius assay or Western Blot to determine the true classification. Specificity and 95% confidence intervals will be calculated.
Sensitivity Serum or plasma (n= 757) repository samples from individuals infected with HIV will be tested at four external sites and at Avioq with up to four validation kit lots. The samples will be tested at all sites in proportions based on the manufacturing size of the individual validation lots. At Site 1 the samples will be further divided approximately 75% I 25% between Validation lots 1 & 2. At Site 2 the samples will be divided approximately 75% / 25%, between Validation lots 2 and 3. At sites 3 and 4 the samples will be tested entirely with Validation lot 3. A fourth lot (Validation lot 5) will be used to test a few HIV-1 Group O samples at Avioq. The study design calls for the use of at least one lot in common at all 4 clinical sites based on a request from the FDA.
The sensitivity samples will consist of 400 HIV positives, a minimum of 200 HIV-2 positives, 50 AIDS positive, 40 pediatric HIV positive, a minimum of 15 HIV-O positives, 10 HIV-1/HIV-2 coinfected positives and a minimum of 27 samples from pregnant females (samples from all three trimesters) infected with HIV.
All specimens are expected to be positive for HIV-1 and/or HIV-2 antibody representing the types of specimens expected to be tested with the Avioq VioOne™ HIV Profile™ Supplemental Assay. Samples with VioOne™ HIV Profile™ assay results discordant from this expectation will be resolved by testing the same samples in FDA approved confirmatory assays such as the BioRad Geenius or Western Blot.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
757 (Actual)
8. Arms, Groups, and Interventions
Arm Title
VioOne HIV Profile
Arm Type
Other
Arm Description
HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2. It is intended as an additional, more specific test to confirm the presence of antibodies to HIV-1 and HIV-2 for specimens repeatedly reactive in diagnosis or screening procedures, including pediatric patients (ages 2-20).
Intervention Type
Device
Intervention Name(s)
VioOne HIV Profile Supplemental Assay
Intervention Description
The VioOne™ HIV Profile™ Supplemental Assay is an enzyme-linked immunosorbent assay (ELISA) for confirmation and differentiation of individual antibodies directed to various gene products of Human Immunodeficiency Virus Type 1 (HIV-1 Group M & Group O) and Type 2 (HIV-2) in human serum or plasma. The HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2.
Primary Outcome Measure Information:
Title
Clinical specificity and sensitivity of HIV Infection
Description
Clinical Specificity and 95% CI of the Profile Assay Clinical Sensitivity and 95% CI of the Profile Assay
Time Frame
9 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
2 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Specificity = 280 Serum Samples and 300 Plasma Samples
An additional 20 Serum pediatric samples
From low risk population (e.g. blood donors)
Sensitivity = 757 Total Samples
400 HIV positive,
200 HIV-2 positive
50 AIDS positive
40 Pediatric
15 HIV-O positive
10 HIV-1/HIV-2 co-infected positive
27 samples from pregnant females with HIV
Facility Information:
Facility Name
Avioq Inc
City
Research Triangle Park
State/Province
North Carolina
ZIP/Postal Code
27712
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
VioOne HIV Profile Supplemental Assay
We'll reach out to this number within 24 hrs